COUNTING THE COST OF MENINGOCOCCAL DISEASE IN FRANCE
Author(s)
Faivre P1;Bénard S*1;Wright C2;Voisine J3, Gaudelus J4 1st[è]ve consultants, Oullins, France, 2Meningitis Research Foundation, Bristol, United Kingdom, 3Méningite France-Association Audrey, Ecouflant, France, 4Hôpital Jean Verdier, Bondy, France
OBJECTIVES: Invasive meningococcal disease (IMD) is life-threatening and can result in severe sequelae. In France, no data has been published on the costs of severe IMD cases. This study aimed to estimate lifelong management costs associated with severe cases of IMD in France. METHODS: Two scenarios were developed: a 6-year old child with purpura fulminans resulting in amputation of both legs below the knee and a 3-year old with meningitis and severe neurological sequelae. Additional scenarios included other typical sequelae of IMD: chronic renal insufficiency (CRI), profound deafness, epilepsy. Scenarios were validated by national experts of IMD. Health, disability, educational and other resources were obtained from experts and families of patients with similar sequelae. Unit costs (2013) were obtained from the literature, the National Health Insurance (NHI) and companies’ websites. Time horizon was based on life expectancies of patients (77 and 55-years respectively). A 4% discount rate decreasing to 2% after 30-years was applied. Costs are presented from NHI, public funded organisations and patient or his/her private health insurance perspectives. RESULTS: Purpura fulminanswith amputations is associated with a lifelong discounted cost of €768,874. Adding CRI doubles the amount (€1,480,545). Meningitis with severe neurological sequelae results in a lifelong discounted cost of €1,924,475. Adding profound deafness and epilepsy slightly increases the total cost (€2,267,251). The first year is the most expensive in both scenarios (€166,890 and €160,647 respectively). The main cost drivers are respectively for each scenario prostheses and child/adult stay in institutions. Overall, NHI covers 1/2 of total cost, public funded organisations 1/3 and patient/private health insurance for the remainder. CONCLUSIONS: This study fills a gap in the body of knowledge on IMD sequalae care and costs in France. The potentially high economic burden of IMD, in addition to its physical, psychological and social burden, reinforces the need for prevention.
Conference/Value in Health Info
2013-11, ISPOR Europe 2013, The Convention Centre Dublin
Value in Health, Vol. 16, No. 7 (November 2013)
Code
PIN35
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
Infectious Disease (non-vaccine), Vaccines